Cargando…

Discovery of 12O—A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor

A novel series of pyrimidine-benzotriazole derivatives have been synthesized and evaluated for their anticancer activity against human solid tumor cell lines. The most promising molecule 12O was identified for its excellent antiproliferative activities, especially against the SiHa cell line with IC(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Yan, Huang, Zhi, Wang, Xiaoshuang, Ma, Yakun, Li, Yongtao, Yang, Shengyong, Shi, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664879/ https://www.ncbi.nlm.nih.gov/pubmed/33182255 http://dx.doi.org/10.3390/molecules25215199

Ejemplares similares

Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control
por: Wang, Xin, et al.
Publicado: (2020)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
por: Huang, Zhi, et al.
Publicado: (2018)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

The Discovery of Aurora Kinase Inhibitor by Multi-Docking-Based Virtual Screening
por: Kim, Jun-Tae, et al.
Publicado: (2014)

Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
por: Hsu, Yung Chang, et al.
Publicado: (2016)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study
por: Srikanthan, Amirrtha, et al.
Publicado: (2015)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges
por: Schneider, Tatiana C., et al.
Publicado: (2016)

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1
por: Degnan, Andrew P., et al.
Publicado: (2021)

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents
por: Wang, Jinfeng, et al.
Publicado: (2017)

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors
por: Serrano-Heras, Gemma, et al.
Publicado: (2015)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
por: Bellantoni, Andrew J., et al.
Publicado: (2021)

A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma
por: Xu, Guangwei, et al.
Publicado: (2018)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors
por: Kalogirou, Andreas S., et al.
Publicado: (2021)

Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Discovery of a Novel Template, 7-Substituted 7-Deaza-4′-Thioadenosine Derivatives as Multi-Kinase Inhibitors
por: Mashelkar, Karishma K., et al.
Publicado: (2021)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
por: Peng, Chunying, et al.
Publicado: (2021)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2- and NCK-interacting Kinase Inhibitor
por: Tan, Zhi, et al.
Publicado: (2016)

Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects
por: Ndolo, Karyn Muzinga, et al.
Publicado: (2019)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Discovery of a selective inhibitor of Doublecortin Like Kinase 1
por: Ferguson, Fleur M., et al.
Publicado: (2020)

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
por: Mologni, Luca, et al.
Publicado: (2022)

Discovery of microRNAs and other small RNAs in solid tumors
por: Meiri, Eti, et al.
Publicado: (2010)

Discovery and characterization of naturally occurring potent inhibitors of catechol-O-methyltransferase from herbal medicines
por: Zhao, Dong-Fang, et al.
Publicado: (2021)

Effect of Tumor Red Blood Cell Immunity and Tumor Cell Cycle in Mice Bearing Solid Liver Cancer with Intelligent Cancer Zhongning Therapeutic Apparatus
por: Ge, Yakun, et al.
Publicado: (2021)

Discovery of New Pyrrolo[2,3-d]pyrimidine Derivatives as Potential Multi-Targeted Kinase Inhibitors and Apoptosis Inducers
por: Alotaibi, AbdulAziz A., et al.
Publicado: (2023)

Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2018)

Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery
por: Satapathy, Sukanta, et al.
Publicado: (2022)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
por: Fan, Bin, et al.
Publicado: (2019)

Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments
por: Latif, Muhammad, et al.
Publicado: (2018)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Correction to “Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase”
por: Mologni, Luca, et al.
Publicado: (2022)

Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis
por: Ray, Mohana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iefhkk5ulsgbqogsu5feb8nfdc